X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (77) 77
humans (66) 66
physics (49) 49
high energy physics - experiment (48) 48
oncology (48) 48
experiment (47) 47
物理学 (46) 46
physics of elementary particles and fields (45) 45
male (44) 44
particle physics (44) 44
fysik (43) 43
natural sciences (43) 43
naturvetenskap (43) 43
physical sciences (43) 43
female (42) 42
carcinoma, renal cell - drug therapy (40) 40
physics - high energy physics - experiment (39) 39
middle aged (38) 38
kidney neoplasms - drug therapy (37) 37
cancer (36) 36
metastasis (32) 32
physics, particles & fields (32) 32
aged (31) 31
carcinoma, renal cell (31) 31
urology & nephrology (31) 31
sunitinib (30) 30
kidney neoplasms - pathology (28) 28
prognosis (27) 27
elementary particles, quantum field theory (25) 25
large hadron collider (25) 25
quantum field theories, string theory (25) 25
renal cell carcinoma (25) 25
survival (25) 25
treatment outcome (25) 25
care and treatment (24) 24
hep (24) 24
high energy physics (24) 24
interferon-alpha (24) 24
retrospective studies (23) 23
antineoplastic agents - therapeutic use (22) 22
targeted therapy (22) 22
urology (22) 22
article (21) 21
carcinoma, renal cell - mortality (21) 21
ex (20) 20
kidney neoplasms - mortality (20) 20
astronomy, astrophysics and cosmology (19) 19
carcinoma, renal cell - secondary (19) 19
collisions (19) 19
hematology, oncology and palliative medicine (19) 19
measurement science and instrumentation (19) 19
nuclear energy (19) 19
nuclear physics, heavy ions, hadrons (19) 19
sorafenib (19) 19
subatomic physics (19) 19
subatomär fysik (19) 19
adult (18) 18
aged, 80 and over (18) 18
disease-free survival (18) 18
everolimus (18) 18
analysis (17) 17
nuclear experiment (17) 17
particle collisions (16) 16
patient outcomes (16) 16
regular - experimental physics (16) 16
neoplasm metastasis (15) 15
vascular endothelial growth factor (15) 15
carcinoma, renal cell - pathology (14) 14
transverse momentum (14) 14
databases, factual (13) 13
indoles - therapeutic use (13) 13
molecular targeted therapy (13) 13
pyrroles - therapeutic use (13) 13
vascular endothelial growth factor a - antagonists & inhibitors (13) 13
detectors (12) 12
luminosity (12) 12
risk factors (12) 12
abridged index medicus (11) 11
antineoplastic agents (11) 11
kaplan-meier estimate (11) 11
model (11) 11
phenomenology (11) 11
survival analysis (11) 11
survival rate (11) 11
hadron (10) 10
quarks (10) 10
research (10) 10
antimitotic agents (9) 9
bevacizumab (9) 9
carcinoma (9) 9
double-blind (9) 9
leptons (9) 9
molecular targeted therapy - methods (9) 9
niacinamide - analogs & derivatives (9) 9
parton distributions (9) 9
phase-iii trial (9) 9
protons (9) 9
standard model (9) 9
time factors (9) 9
trial (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 12/2018, Volume 36, Issue 36, pp. 3567 - 3573
The most common type of cancer originating in the kidney is renal cell carcinoma (RCC). In both localized and advanced RCC, a number of clinical, pathologic,... 
TARGETED THERAPY | RADICAL NEPHRECTOMY | SURVIVAL | IMPACT | ONCOLOGY | HIGH-RISK | VALIDATION | MODEL | RETROSPECTIVE ANALYSIS | RENAL-CELL CARCINOMA | ADJUVANT SUNITINIB
Journal Article
The Oncologist, ISSN 1083-7159, 12/2017, Volume 22, Issue 12, pp. 1561 - 1561
This letter responds to the letter from Tan et al., noting points of agreement and encouraging efforts to share genomic signatures and codes that will make... 
Letters to the Editor
Journal Article
The Oncologist, ISSN 1083-7159, 12/2017, Volume 22, Issue 12, pp. 1561 - 1561
This letter responds to the letter from Tan et al., noting points of agreement and encouraging efforts to share genomic signatures and codes that will make... 
Journal Article
The Oncologist, ISSN 1083-7159, 12/2017, Volume 22, Issue 12, pp. 1561 - 1561
Journal Article
Current Opinion in Urology, ISSN 0963-0643, 09/2019, Volume 29, Issue 5, pp. 507 - 512
PURPOSE OF REVIEWTo review the evidence related to cytoreductive nephrectomy in metastatic renal cell carcinoma (mRCC) treated in the targeted therapy era,... 
Care and treatment | Carcinoma, Renal cell | Metastasis | Nephrectomy | Patient outcomes
Journal Article
European urology, ISSN 0302-2838, 08/2019
In metastatic renal-cell carcinoma (mRCC), recent data have shown efficacy of first-line ipilimumab and nivolumab (ipi-nivo) as well as immuno-oncology... 
Journal Article
Journal of Oncology Practice, ISSN 1554-7477, 07/2017, Volume 13, Issue 7, pp. 422 - 423
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2015, Volume 373, Issue 19, pp. 1814 - 1823
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 7, pp. 917 - 927
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2017, Volume 35, Issue 34, pp. 3851 - 3858
Purpose Combination treatment with immune checkpoint inhibitors has shown enhanced antitumor activity compared with monotherapy in tumor types such as... 
EVEROLIMUS | ONCOLOGY | Index Medicus
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 2016, Volume 50, pp. 109 - 117
Highlights • Survival of patients with mRCC has improved since the advent of targeted therapy. • Identification of prognostic biomarkers may advance... 
Hematology, Oncology and Palliative Medicine | Prognostic markers | Predictive markers | Sequential therapy | Overall survival | Targeted therapy | mRCC | PROGNOSTIC-FACTORS | PROGRESSION-FREE SURVIVAL | 1ST-LINE SUNITINIB | OPEN-LABEL | PHASE-III TRIAL | INTERFERON-ALPHA | ONCOLOGY | DOUBLE-BLIND | 2ND-LINE TREATMENT | CANCER-SPECIFIC SURVIVAL | CLINICAL-PRACTICE | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Kidney Neoplasms - genetics | Bevacizumab - therapeutic use | Prognosis | Humans | Gene Expression Regulation, Neoplastic | Carcinoma, Renal Cell - genetics | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Kidney Neoplasms - metabolism | Vascular Endothelial Growth Factor A - genetics | Sunitinib | Tumor Suppressor Proteins - genetics | Biomarkers, Tumor - metabolism | Axitinib | Everolimus - therapeutic use | Von Hippel-Lindau Tumor Suppressor Protein - genetics | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Nuclear Proteins - genetics | Pyrroles - therapeutic use | Molecular Targeted Therapy - methods | Pyridines - therapeutic use | Histone-Lysine N-Methyltransferase - genetics | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Receptors, CCR4 - genetics | Interferon-alpha - therapeutic use | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Transcription Factors - genetics | Ubiquitin Thiolesterase - genetics | Carcinoma, Renal Cell - metabolism | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Carcinoma, Renal Cell - secondary | Nivolumab | Sorafenib | Indoles - therapeutic use | Kidney Neoplasms - pathology | MicroRNAs - genetics | Quinolines - therapeutic use | Mutation | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Precision Medicine - methods | Immunologic Factors - therapeutic use | Antimitotic agents | Care and treatment | Metastasis | Antineoplastic agents | Patient outcomes | Cancer
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 02/2014, Volume 143, Issue 3, p. 459
The present exploratory analysis examined the efficacy, safety, and quality-of-life effects of everolimus (EVE) + exemestane (EXE) in the subgroup of patients... 
Care and treatment | Breast cancer | Postmenopausal women | Angiogenesis inhibitors | Analysis
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.